Merck Keytruda, anti-TIGIT therapy coformulation hits setback in mid-stage trial
JasonDoiy
- The open-label portion of a phase 2 trial examining a coformulation of Merck's Keytruda (pembrolizumab) and the experimental anti-TIGIT therapy vibostolimab failed to meet its primary endpoint.
- That endpoint, progression-free survival, was less effective compared to docetaxel. The open label portion was evaluating the coformulation, known as MK-7684, alone compared to docetaxel in patients with non-small cell lung cancer.
- Merck (NYSE:MRK) will continue the two blinded arms of MK-7684 that are evaluating it with docetaxel vs. docetaxel alone.
- The pharma has four other MK-7684 phase 3 studies underway for lung cancer, and another for melanoma.
- Read why Seeking Alpha contributor Cory Cramer rates Merck (MRK) a hold.